VentriPoint Diagnostics Ltd (CVE:VPT) has built a prototype of an improved version of its VMS-plus heart analysis system.
This new device, designated VMS-plus 3.0, is undergoing final testing and development to verify its performance.
The new design eliminates the need for patients to remain motionless during image acquisition and improves the work-flow of the VMS-plus through a more intuitive user interface, Ventripoint said.
The new device will reduce the cost of its equipment significantly and allow a “per-use” sales model that is expected to prove especially appealing to small and medium-sized medical centres.
The company intends to offer both a capital purchase as well as the subscription option to customers starting in 2019.
Shares in VentriPoint were up 4.4% at C$0.24.